Дмитрий Андреевич Козин

Дмитрий Андреевич Козин

Auto-generated profile, based on publicly available information

Дмитрий Андреевич Козин

ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2020 in Drug development & registration
Verified
Journal Article
Open access
PDF file
DKD. A. Kozin
D. A. Kozin
ZSZoya Shprakh
Zoya Shprakh
VRV. Yu. Reshetnyak
V. Yu. Reshetnyak
ONOlga Vladimirovna Nesterova
Olga Vladimirovna Nesterova
IAI. N. Avertseva
I. N. Avertseva
ВРВ. Ю. Решетняк
В. Ю. Решетняк
Introduction. Currently, more than 600 thousand people a year are affected by malignant tumors on the territory of the Russian Federation. Despite the large selection of antitumor drugs and the variety of mechanisms of their action, the effectiveness of existing drugs continues to be insufficient. The main disadvantages of most antitumor drugs are the emergence of tolerance to them of tumor cells, a limited range of action and high toxicity. In this regard, the creation of effective original domestic antitumor drugs still remains relevant. Among the numerous natural and synthetic heterocyclic compounds that exhibit antitumor activity, indolo[2,3-a]carbazole derivatives that can initiate various pathways of tumor cell death are of increasing interest. The main targets for their action are topoisomerases and protein kinases, which play an important role in the processes of replication, transcription, repair or recombination of deoxyribonucleic acid (DNA). Due to this, in addition to antitumor activity, this group of compounds shows antibacterial, аntiprotozoal and immunomodulatory activity, which makes them a very promising class of candidates for the creation of new drugs.Text. The purpose of this review is to discuss instrumental methods for qualitative and quantitative analysis of indolo[2,3-a]carbazole derivatives used in the world's leading pharmacopoeias. These methods can be used both in pharmacokinetic studies, and in the standardization of these compounds, in the form of pharmaceutical substances, or as part of drug forms.Conclusion. To further introduce a new group of antitumor drugs based on indole[2,3-a]carbazole derivatives into medical practice, a deep and thorough study of their physical and chemical properties is necessary. Justification and development of analysis methods allow us to develop methods applicable to pharmacokinetic studies, as well as to create regulatory documents for quality control and standardization of indolo[2,3-a] carbazole derivatives as pharmaceutical substances. A study of the literature that describes methods for analyzing indolo[2,3-a]carbazole derivatives indicates that spectrometric (infrared and ultraviolet spectrometry) and chromatographic (thin-layer chromatography and high-performance liquid chromatography) methods are most often used to determine the authenticity and quantitative analysis of these compounds.

30 January 2023 in "Medical & Pharmaceutical Journal "Pulse"
Verified
Journal Article
Closed access
KDKozin D.A.
Kozin D.A.
SZShprakh Z.S.
Shprakh Z.S.
BABudko A.P.
Budko A.P.
PRPugacheva R.B.
Pugacheva R.B.
ELEktova L.V.
Ektova L.V.
ONOlga Vladimirovna Nesterova
Olga Vladimirovna Nesterova
The N.N. Blokhin Oncology Research Center synthesized indolo[2,3-a]carbazole N-glycoside, which received the laboratory cipher LСS-1269, which showed a pronounced antitumor effect during research.. During the study of LСS-1269 by HPLC, the presence of two impurities was revealed, called LСS-1269-X and LСS-1269-Y (impurities X and Y). The electronic absorption spectrum (EAS) of the impurity peak X was similar to the EAS of the indolo[2,3-a]carbazole N-glycoside obtained and described earlier under the laboratory cipher LCS-1208, and the EAS of the impurity was the spectrum of LCS–1269, which indicates that the impurities belong to indolo[2,3-a]carbazoles. In this regard, it is suggested about the structure of these impurities: impurity X is a xyloside of aglycone similar in structure to aglycone LCS-1208, which can be formed as a by-product at one of the last stages of the synthesis of LCS-1269, and impurity Y has the structure of triacetyl ester LCS-1269, which is a precursor of LCS-1269 in the synthesis process. The aim of the work was to identify impurities in the substance LHS-1C69, to confirm their structures and belonging to derivatives of indolo[2,3-a]carbazole. The identification of impurities in the substance LCS-1269 was carried out using the HPLC-MSMS method. For this purpose, X and Y impurities having the assumed structures were obtained by directed counter synthesis, which were used as reference samples. Comparison of peak retention times on extracted ion chromatograms (XIC) and MSMS spectra of impurities with XIC and MSMS spectra of samples of comparison of the alleged impurities confirmed their structure. As a result of the work carried out, the structures of impurities X and Y were identified and the affiliation of these impurities to derivatives of indolo[2,3-a]carbazole was confirmed.

28 August 2021 in Drug development & registration
Verified
Journal Article
Open access
PDF file
ЕИЕ. В. Игнатьева
Е. В. Игнатьева
IYI. V. Yartseva
I. V. Yartseva
ZSZoya Shprakh
Zoya Shprakh
ABA. P. Bud'KO
A. P. Bud'KO
LEL. V. Ektova
L. V. Ektova
ВРВ. Ю. Решетняк
В. Ю. Решетняк
Introduction. Indolocarbazole derivatives are of increasing scientific interest for practical oncology. A number of N-glycosides, indolo[2,3-a] carbazole under the laboratory code LCS, were synthesized in the laboratory of chemical synthesis of the National Medical Center of Oncology named after N.N. Blokhin. Currently, one of the most promising compounds in this class is LCS-1208, a representative of the arabinoside class of indolo [2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione. According to the mechanism of biological action, LCS-1208 is a protein kinase C inhibitor and is of great interest for the treatment of malignant neoplasms.Aim. chemical and pharmaceutical standardization of the pharmaceutical substance LCS-1208.Materials and methods. Laboratory samples of pharmaceutical substance LCS-1208. Methods of investigation: gravimetry, spectrophotometry, polarimetry, high-performance liquid chromatography (HPLC), high-resolution nuclear magnetic resonance (NMR) spectroscopy and infrared (IR) spectroscopy.Results and discussion. The quality assessment of LCS-1208 was carried out according to the indicators adopted in the XIV edition of the State Pharmacopoeia of the Russian Federation for quality control of pharmaceutical substances. LCS-1208 - orange amorphous powder, odorless; soluble in dimethylsulfoxide (DMSO) and dimethylformamide (DMF); very slightly soluble in 95 % ethyl alcohol and practically insoluble in water. The authenticity of the substance is confirmed by NMR and IR spectra, as well as electronic absorption spectra. The values of the specific optical rotation of LCS-1208 (1 % solution in DMF) are placed in the range from +58° to +61°. All the studied samples of the substance were free of inorganic impurities, sulphate ash, heavy metals and contained no more than 1.0 % water, determined by the K. Fischer titration method. The content of possible related impurities in the substance LCS-1208 and the content of the main active substance were determined by HPLC. The studied laboratory series of the pharmaceutical substance LCS-1208 contained no more than 1.0 % of any single and no more than 3 % of the total unidentified impurities. The content of the main active substance was more than 97 %.Conclusion. As a result of the work carried out, quality criteria and parameters were selected and methods for their determination were developed, which allow to adequately assess the quality and standardness of the pharmaceutical substance LCS-1208.

27 December 2024 in Химико-фармацевтический журнал
Verified
Journal Article
Closed access
PDF file
ЗШЗоя Сергеевна Шпрах
Зоя Сергеевна Шпрах
ЕИЕлена Владимировна Игнатьева
Елена Владимировна Игнатьева
ДКДмитрий Андреевич Козин
Дмитрий Андреевич Козин
ALAnna Lantsova
Anna Lantsova
LNLudmila Nikolaeva
Ludmila Nikolaeva
ГВГусев Дмитрий Васильевич
Гусев Дмитрий Васильевич
В ФГБУ «НМИЦ онкологии им. Н. Н. Блохина синтезировано оригинальное химическое соединение из класса N-гликозидов индоло[2,3-a]карбазолов (ЛХС-1269) с выраженной противоопухолевой активностью, и получена его лекарственная форма для инъекционного введения. Для количественной оценки ЛХС-1269 в лекарственной форме разработаны методики спектрофотометрического и хроматографического определения. Сравнительный анализ валидационных характеристик двух методик показал, что они специфичны, линейны, свободны от систематических ошибок, не отличаются по прецизионности и могут быть использованы для количественного определения ЛХС-1269 в лекарственной форме. Метод ВЭЖХ предпочтительнее, поскольку пределы обнаружения и количественного определения ВЭЖХ-методики более чем в 100 раз ниже, чем для метода спектрофотометрии.

15 July 2025 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
DKD. A. Kozin
D. A. Kozin
NKN. Yu. Kulbachevskaya
N. Yu. Kulbachevskaya
VBV. A. Balykov
V. A. Balykov
ZSZoya Shprakh
Zoya Shprakh
Background. The glycosylated derivative of indolo[2,3-a]carbazole LCS-1269, an DNA intercalator and a chromatin remodulator, synthesized in N.N. Blokhin National Medical Research Center of Oncology (N.N. Blokhin NMRCO), is of great interest for the treatment of malignant tumors. To carry out pharmacokinetic studies of LCS-1269 dosage forms in vivo, it is necessary to develop a method for LCS-1269 assay in biological samples.Aim. To develop and validate an analytical technique using high-performance liquid chromatography with ultraviolet detection (HPLC-UV) for LCS-1269 pharmacokinetic studies.Materials and methods. The study used the LCS-1269 substance containing 99.4 % of the active component, blood plasma and liver of healthy cyclic immunocompetent laboratory mice hybrid (C57Bl/6J×DBA2) F1 of N.N. Blokhin NMRCO breeding. Acetonitrile and sodium chloride were used to prepare biological samples. Reversed-phase HPLC-UV method in the gradient regimen was used for LCS-1269 assay. Statistical processing of the obtained results was carried out in Microsoft Office Excel 2010 software.Results. The technique based on cooled acetonitrile deproteinization was developed for blood plasma sample preparation; liver samples were prepared using combined cooled acetonitrile and sodium chloride deproteinization. The developed technique validation confirmed its specificity, linearity (r 0.99), correctness (response 80 % at low concentrations) and precision (relative standard deviation 3.5 %) in the entire analytical range; LCS-1269 transfer effect wasn’t observed. It was found that the analyzed samples are stable for 24 hours at room temperature, and the model mixtures are stable during a month when stored at temperatures less than –18 °C.Conclusion. A bioanalytical technique for LCS-1269 assay in the blood plasma and liver of animals using HPLC-UV has been developed. Has been shown that the technique meets the requirements of the Eurasian Economic Union for the validation of biological samples analysis.

15 July 2026 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
EIElena V. Ignateva
Elena V. Ignateva
ИВИгнатьева Елена Владимировна
Игнатьева Елена Владимировна
IYIrina V. Yartseva
Irina V. Yartseva
ЯВЯрцева И. В.
Ярцева И. В.
DKDmitry A. Kozin
Dmitry A. Kozin
ШСШпрах З. С.
Шпрах З. С.
Background. The development of innovative national antitumor drugs remains an ultimately important task. Among the new drugs, which selectively affect tumors, indolo [2,3-a] carbazole – N-glycosides LCS-1208 and LCS-1269, synthesized using an original technique at the Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, are of essential interest. The paper presents possible options of instrumental analytical methods for identification of differences in the physical chemical features of structurally similar compounds LCS-1208 and LC S-1269. These methods may be used for establishing experimentally justified standards of quality for the standardization of the compounds as pharmaceutical substances. Aim. To study the physical chemical features and to develop methods for the qualitative and quantitative analysis of LCS-1208 and LCS-1269. Materials and methods. The study involved modern instrumental methods of analysis, such as polarimetry, ultraviolet spectroscopy, infrared spectroscopy, proton magnetic resonance spectroscopy spectroscopy, high performance liquid chromatography (HPLC), and HPLC with the tandem mass spectrometric detection (HPLC–MS / MS). Results. Significant differences in the physical chemical features of the original N-glycosides LCS-1208 and LCS-1269 were determined using modern instrumental analytical methods. The authors present the results verifying the structure of each of these compounds. The methods for qualitative and quantitative analysis of these compounds were developed in the study. The HPLC validation was performed for the LCS-1269 quantification method. The study showed the compliance of the obtained validation characteristics with the criteria approved by the Russian State Pharmacopoeia XV Ed and Pharmacopoeia of the Eurasian Economic Union. The authors determined the structure of impurities in LCS-1269 samples and proposed a method for their quantitative determination. Conclusion. Structures of indolo [2,3-a] carbazole derivatives LCS-1208 and LCS-1269 were confirmed and shown to be reliably distinguishable. Impurity structures from the final LHS-1269 synthesis step were identified. HPLC methods for quantifying LCS-1208 and LCS-1269 were developed.